Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Telitacicept - Yantai Rongchang Pharmaceutical

Next Previous
Drug Profile

Telitacicept - Yantai Rongchang Pharmaceutical

Alternative Names: RC-18; RC18-L; RCT-18; Tai’ai

Latest Information Update: 10 Sep 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator RemeGen
  • Developer RemeGen; Vor Biopharma
  • Class Antirheumatics; Eye disorder therapies; Immunoglobulin Fc fragments; Recombinant fusion proteins; Urologics
  • Mechanism of Action B cell activating factor inhibitors; Tumour necrosis factor ligand superfamily member 13 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Myasthenia gravis
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed IgA nephropathy; Myasthenia gravis; Rheumatoid arthritis; Sjogren's syndrome; Systemic lupus erythematosus
  • Phase III Neuromyelitis optica
  • Phase II Lupus nephritis; Multiple sclerosis

Most Recent Events

  • 08 Sep 2026 RemeGen completes enrolment in the phase III UPSTREAM MG trial in Myasthenia gravis in USA, Argentina, China, Australia, Belgium, Brazil, Canada, Czech Republic, Japan, France, Georgia, Italy, Poland and Spain (SC) (NCT06456580)
  • 08 Sep 2026 RemeGen plans a global phase III UPSTREAM oMG trial for Myasthaneia gravis in first half of 2027
  • 08 Jun 2026 Launched for IgA nephropathy in China (SC)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top